trending Market Intelligence /marketintelligence/en/news-insights/trending/xKmZAhrhxVC6Hkned1Z25Q2 content esgSubNav
In This List

Q BioMed completes equity financing

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Q BioMed completes equity financing

Q BioMed Inc. completed an equity financing of about $3.1 million with a group of accredited investors.

The biotech company sold 953,247 units to the investors, with each unit consisting of 1 common share priced at $3.20 and a five-year warrant to purchase 1 additional common share at $4.50.

The proceeds will be used for producing Strontium Chloride Sr-89, which is approved by the U.S. Food and Drug Administration as a generic painkiller for patients suffering from metastatic bone cancer, and for work on its investigational new drug application for QBM001, a treatment for young children suffering from a rare autistic spectrum disorder that causes them to lose the ability to speak.

Brookline Capital Markets, a division of CIM Securities LLC acted as the exclusive placement agent for the offering.